CN1225568A - 用于雌二醇与另一种类固醇物质共同给药的透皮释药基质 - Google Patents
用于雌二醇与另一种类固醇物质共同给药的透皮释药基质 Download PDFInfo
- Publication number
- CN1225568A CN1225568A CN97196563A CN97196563A CN1225568A CN 1225568 A CN1225568 A CN 1225568A CN 97196563 A CN97196563 A CN 97196563A CN 97196563 A CN97196563 A CN 97196563A CN 1225568 A CN1225568 A CN 1225568A
- Authority
- CN
- China
- Prior art keywords
- preparation
- lot
- flux
- estradiol
- steroid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003431 steroids Chemical class 0.000 title claims abstract description 51
- 229960005309 estradiol Drugs 0.000 title claims abstract description 32
- 229930182833 estradiol Natural products 0.000 title claims abstract description 32
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 title claims abstract description 31
- 239000011159 matrix material Substances 0.000 title abstract description 21
- 238000013271 transdermal drug delivery Methods 0.000 title 1
- 230000004907 flux Effects 0.000 claims abstract description 93
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims abstract description 27
- 229920006243 acrylic copolymer Polymers 0.000 claims abstract description 21
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims abstract description 9
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 70
- 229960003604 testosterone Drugs 0.000 claims description 35
- 239000000126 substance Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 17
- 229920001577 copolymer Polymers 0.000 claims description 13
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 claims description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- 230000002500 effect on skin Effects 0.000 claims description 2
- 238000002657 hormone replacement therapy Methods 0.000 claims description 2
- 238000011282 treatment Methods 0.000 claims description 2
- 239000003961 penetration enhancing agent Substances 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 description 174
- 210000003491 skin Anatomy 0.000 description 74
- 239000000758 substrate Substances 0.000 description 67
- 239000000853 adhesive Substances 0.000 description 52
- 230000001070 adhesive effect Effects 0.000 description 52
- 239000003814 drug Substances 0.000 description 33
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 30
- 238000009792 diffusion process Methods 0.000 description 19
- 239000000203 mixture Substances 0.000 description 18
- 241000769223 Thenea Species 0.000 description 16
- 229940079593 drug Drugs 0.000 description 13
- 238000003475 lamination Methods 0.000 description 13
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 9
- 238000009825 accumulation Methods 0.000 description 9
- 238000005266 casting Methods 0.000 description 9
- NWGKJDSIEKMTRX-BFWOXRRGSA-N [(2r)-2-[(3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)C1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-BFWOXRRGSA-N 0.000 description 8
- 238000012417 linear regression Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000000654 additive Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 5
- 230000000996 additive effect Effects 0.000 description 5
- -1 estradiol ester Chemical class 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 230000035515 penetration Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 2
- 238000003255 drug test Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 229960004400 levonorgestrel Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- UQDUPQYQJKYHQI-UHFFFAOYSA-N methyl laurate Chemical compound CCCCCCCCCCCC(=O)OC UQDUPQYQJKYHQI-UHFFFAOYSA-N 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 238000010010 raising Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 1
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 1
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000252233 Cyprinus carpio Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 241001411320 Eriogonum inflatum Species 0.000 description 1
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002313 adhesive film Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 1
- 229960005471 androstenedione Drugs 0.000 description 1
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 1
- 229920005601 base polymer Polymers 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 description 1
- 229960004976 desogestrel Drugs 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002168 ethanoic acid esters Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 description 1
- 229960005352 gestodene Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000011229 interlayer Substances 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical class [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 229960001566 methyltestosterone Drugs 0.000 description 1
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 1
- 229940053934 norethindrone Drugs 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- BVWMJLIIGRDFEI-QXMHVHEDSA-N propyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCC BVWMJLIIGRDFEI-QXMHVHEDSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Abstract
Description
制剂ID | TSR胶粘剂 | NEA | E2 | ARLACEL80 |
%w/w | %w/w | %w/w | %w/w | |
待测制剂 | ||||
1.Lot#040695-1 | 88.5 | 1.5 | 0.0 | 10.0 |
2.Lot#040695-2 | 87.0 | 3.0 | 0.0 | 10.0 |
3.Lot#040695-3 | 84.0 | 6.0 | 0.0 | 10.0 |
参比制剂 | ||||
4.参比#95Z007NEA参比制剂 | 77.8 | 6.0 | 6.2 | 10.0 |
制剂ID | 皮肤/池的# | Q96* | 比例+ |
待测制剂 | |||
1.Lot#040695-1 | 6/24 | 8.4±2.5 | 0.27±0.06 |
2.Lot#040695-2 | 6/24 | 17.3±3.8 | 0.55±0.10 |
3.Lot#040695-3 | 6/24 | 32.9±8.9 | 1.00±0.08 |
制剂ID | TSR胶粘剂 | NEA | E2 | ARLACEL80 |
%w/w | %w/w | %w/w | %w/w | |
待测制剂 | ||||
5.Lot#040695-4 | 87.0 | 0.0 | 3.0 | 10.0 |
6.Lot#040695-8 | 83.8 | 0.0 | 6.2 | 10.0 |
7.Lot#040695-12 | 81.0 | 0.0 | 9.0 | 10.0 |
参比制剂 | ||||
8.参比#94Z003E2参比制剂 | 93.5* | 0.0 | 1.5 | 5.0 |
制剂ID | 皮肤/池的# | Q96* | 比例+ |
待测制剂 | |||
5.Lot#040695-4 | 6/24 | 6.1±1.7 | 0.29±0.06 |
6.Lot#040695-8 | 6/24 | 13.4±4.0 | 0.64±0.08 |
7.Lot#040695-12 | 6/24 | 20.9±5.6 | 1.0±0.16 |
制剂ID | TSR胶粘剂 | NEA | E2 | ARLACEL80 |
%w/w | %w/w | %w/w | %w/w | |
待测制剂 | ||||
9.Lot#040695-5 | 85.5 | 1.5 | 3.0 | 10.0 |
10.Lot#040695-6 | 84.0 | 3.0 | 3.0 | 10.0 |
11.Lot#040695-7 | 81.0 | 6.0 | 3.0 | 10.0 |
12.Lot#040695-9 | 82.3 | 1.5 | 6.2 | 10.0 |
13.Lot#040695-10 | 80.8 | 3.0 | 6.2 | 10.0 |
14.Lot#040695-11 | 77.8 | 6.0 | 6.2 | 10.0 |
15.Lot#040695-12 | 79.5 | 1.5 | 9.0 | 10.0 |
16.Lot#040695-14 | 78.0 | 3.0 | 9.0 | 10.0 |
17.Lot#040695-15 | 75.0 | 6.0 | 9.0 | 10.0 |
参比制剂 | ||||
4.参比#95Z007NEA参比制剂 | 77.8 | 6.0 | 6.2 | 10.0 |
8.参比#94Z003E2参比制剂 | 93.5* | 0.0 | 1.5 | 5.0 |
制剂ID | 皮肤/扩散池的# | NEA数据 | E2数据 | ||||
Q96* | Q96(参比)x | 比例 | Q96* | Q96(参比)x | 比例 | ||
9.Lot#040695-5 | 7/28 | 7.7±3.6 | 25.7±11.0 | 0.29±0.02 | 5.4±2.4 | 18.7±6.8 | 0.28±0.03 |
10.Lot#040695-6 | 7/28 | 15.4±6.3 | 25.7±11.0 | 0.6±0.08 | 5.7±2.3 | 18.7±6.8 | 0.30±0.02 |
11.Lot#040695-7 | 7/28 | 27.6±11.0 | 25.7±11.0 | 1.1±0.09 | 5.4±2.5 | 18.7±6.8 | 0.28±0.04 |
12.Lot#040695-9 | 5/20 | 7.0±1.9 | 27.8±7.7 | 0.25±0.03 | 10.1±2.7 | 15.8±5.5 | 0.65±0.10 |
13.Lot#040695-10 | 5/20 | 14.2±4.2 | 27.8±7.7 | 0.51±0.05 | 10.4±3.5 | 15.8±5.5 | 0.66±0.03 |
14.Lot#040695-11 | 5/20 | 27.8±7.7 | 27.8±7.7 | 1.0±0.0 | 10.2±3.0 | 15.8±5.5 | 0.66±0.06 |
15.Lot#040695-13 | 6/24 | 8.9±2.6 | 37.4±22.3 | 0.28±0.10 | 20.3±7.5 | 24.7±16.3 | 0.97±0.30 |
16.Lot#040695-14 | 6/24 | 18.3±8.7 | 37.4±22.3 | 0.53±0.12 | 23.0±13.5 | 24.7±16.3 | 0.99±0.17 |
17.Lot#040695-15 | 6/24 | 32.4±18.0 | 37.4±22.3 | 0.90±0.12 | 21.3±13.2 | 24.7±16.3 | 0.89±0.17 |
制剂ID | DUROTAK87-2516胶粘剂 | NEA | E2 | ARLACEL80 |
%w/w | %w/w | %w/w | %w/w | |
待测制剂 | ||||
1.Lot # 013096-1 | 88.0 | 2.0 | 0.0 | 10.0 |
2.Lot # 013096-2 | 86.0 | 4.0 | 0.0 | 10.0 |
3.Lot # 013096-3 | 84.0 | 6.0 | 0.0 | 10.0 |
4.Lot # 013096-4 | 82.0 | 8.0 | 0.0 | 10.0 |
参比制剂 | ||||
5.参比 # 95Z098NEA/E2参比制剂 | 77.6 | 6.0 | 6.4 | 10.0 |
制剂ID | 皮肤/扩散池的# | Q24* | 比例+ |
待测制剂 | |||
1.Lot # 013096-1 | 3/12 | 1.8±0.7 | 0.5±0.2 |
2.Lot # 013096-2 | 3/12 | 3.5±1.1 | 0.9±0.3 |
3.Lot # 013096-3 | 3/12 | 5.4±0.7 | 1.4±0.4 |
4.Lot # 013096-4 | 3/12 | 8.6±4.7 | 2.3±1.8 |
制剂ID | DUROTAK87-2516胶粘剂 | NEA | E2 | ARLACEL80 |
%w/w | %w/w | %w/w | %w/w | |
待测制剂 | ||||
6.Lot # 013096-5 | 89.0 | 0.0 | 1.0 | 10.0 |
7.Lot # 013096-10 | 88.0 | 0.0 | 2.0 | 10.0 |
8.Lot # 013096-15 | 86.0 | 0.0 | 4.0 | 10.0 |
参比制剂 | ||||
4.参比 # 95Z098NEA/E2参比制剂 | 77.6* | 6.0 | 6.4 | 10.0 |
制剂ID | 皮肤/扩散池的# | Q24* | 比例+ |
待测制剂 | |||
6.Lot # 013096-5 | 3/12 | 3.5±1.1 | 1.4±0.5 |
7.Lot # 013096-10 | 3/12 | 6.2±1.1 | 2.4±0.3 |
8.Lot # 013096-15 | 3/12 | 9.0±3.0 | 3.5±1.0 |
制剂ID | DUROTAK87-2516胶粘剂 | NEA | E2 | ARLACEL80 |
%w/w | %w/w | %w/w | %w/w | |
待测制剂 | ||||
9.Lot # 013096-6 | 87.0 | 2.0 | 1.0 | 10.0 |
10.Lot # 013096-7 | 85.0 | 4.0 | 1.0 | 10.0 |
11.Lot # 013096-8 | 83.0 | 6.0 | 1.0 | 10.0 |
12.Lot # 013096-9 | 81.0 | 8.0 | 1.0 | 10.0 |
13.Lot # 013096-11 | 86.0 | 2.0 | 2.0 | 10.0 |
14.Lot # 013096-12 | 84.0 | 4.0 | 2.0 | 10.0 |
15.Lot # 013096-13 | 82.0 | 6.0 | 2.0 | 10.0 |
16.Lot # 013096-14 | 80.0 | 8.0 | 2.0 | 10.0 |
17.Lot # 013096-16 | 84.0 | 2.0 | 4.0 | 10.0 |
18.Lot # 013096-17 | 82.0 | 4.0 | 4.0 | 10.0 |
19.Lot # 013096-18 | 80.0 | 6.0 | 4.0 | 10.0 |
20.Lot # 013096-19 | 78.0 | 8.0 | 4.0 | 10.0 |
参比制剂 | ||||
5.参比#95Z098NEA/E2参比制剂 | 77.6* | 6.0 | 6.4 | 10.0 |
制剂ID | 皮肤/扩散池的# | NEA数据 | E2数据 | ||||
Q24* | Q24(参比)X | 比例 | Q24* | Q24(参比)X | 比例+ | ||
待测制剂 | |||||||
9.Lot # 013096-6 | 3/12 | 4.6±1.3 | 7.6±2.2 | 0.6±0.1 | 5.3±1.5 | 3.3±1.0 | 1.6±0.3 |
10.Lot # 013096-7 | 3/12 | 9.4±2.1 | 7.6±2.2 | 1.2±0.2 | 5.3±1.2 | 3.3±1.0 | 1.6±0.2 |
11.Lot # 013096-8 | 3/12 | 13.8±4.8 | 7.6±2.2 | 1.8±0.5 | 5.1±1.7 | 3.3±1.0 | 1.5±0.3 |
12.Lot # 013096-9 | 3/12 | 17.5±5.6 | 7.6±2.2 | 2.3±0.6 | 5.1±1.7 | 3.3±1.0 | 1.5±0.3 |
13.Lot # 013096-11 | 3/12 | 2.5±0.5 | 6.1±2.6 | 0.4±0.1 | 5.9±1.3 | 2.8±1.2 | 2.2±0.6 |
14.Lot # 013096-12 | 3/12 | 4.8±1.2 | 6.1±2.6 | 0.8±0.3 | 5.3±1.4 | 2.8±1.2 | 2.0±0.7 |
15.Lot # 013096-13 | 3/12 | 7.7±1.8 | 6.1±2.6 | 1.4±0.5 | 5.5±1.3 | 2.8±1.2 | 2.1±0.8 |
16.Lot # 013096-14 | 3/12 | 7.8±2.7 | 6.1±2.6 | 1.3±0.6 | 4.2±1.6 | 2.8±1.2 | 1.6±0.8 |
17.Lot # 013096-16 | 3/12 | 2.8±0.7 | 8.1±2.4 | 0.4±0.04 | 12.8±2.7 | 3.2±0.8 | 4.0±0.4 |
18.Lot # 013096-17 | 3/12 | 5.6±1.5 | 8.1±2.4 | 0.7±0.2 | 11.8±3.0 | 3.2±0.8 | 3.8±1.2 |
19.Lot # 013096-18 | 3/12 | 7.4±1.5 | 8.1±2.4 | 0.9±0.2 | 9.6±1.9 | 3.2±0.8 | 3.1±0.6 |
20.Lot # 013096-19 | 3/12 | 8.2±22 | 8.1±2.4 | 1.1±0.2 | 6.9±1.4 | 3.2±0.8 | 2.2±0.4 |
制剂ID | TSR胶粘剂 | TS | E2 | ARLACEL80 |
%w/w | %w/w | %w/w | %w/w | |
待测制剂 | ||||
1.Lot # 012496-1 | 87.5 | 2.5 | 0.0 | 10.0 |
2.Lot # 012496-2 | 86.25 | 3.75 | 0.0 | 10.0 |
3.Lot # 012496-3 | 85.0 | 5.0 | 0.0 | 10.0 |
参比制剂 | ||||
4.参比 # 95Z082TSR参比制剂 | 75.75 | 3.75 | 10.5 | 10.0 |
制剂ID | 皮肤/扩散池的# | Q24* | 比例+ |
待测制剂 | |||
1.Lot # 012496-1 | 3/12 | 15.6±6.6 | 0.63±0.09 |
2.Lot # 012496-2 | 3/12 | 25.7±13.4 | 1.01±0.20 |
3.Lot # 012496-3 | 3/12 | 31.8±15.3 | 1.28±0.29 |
制剂ID | TSR胶粘剂 | TS | E2 | ARLACEL80 |
%w/w | %w/w | %w/w | %w/w | |
待测制剂 | ||||
5.Lot # 012496-4 | 87.0 | 0.0 | 3.0 | 10.0 |
6.Lot # 012496-8 | 84.0 | 0.0 | 6.0 | 10.0 |
7.Lot # 012496-12 | 79.5 | 0.0 | 10.5 | 10.0 |
参比制剂 | ||||
8.参比 # 95Z135E2参比制剂 | 93.5* | 0.0 | 1.5 | 5.0 |
制剂ID | 皮肤/扩散池的# | Q24* | 比例+ |
待测制剂 | |||
5.Lot # 012496-4 | 3/12 | 2.6±0.7 | 0.28±0.06 |
6.Lot # 012496-8 | 3/12 | 5.4±0.9 | 0.60±0.14 |
7.Lot # 012496-12 | 3/12 | 9.3±1.6 | 1.02±0.18 |
制剂ID | TSR胶粘剂 | TS | E2 | ARLACEL80 |
%w/w | %w/w | %w/w | %w/w | |
待测制剂 | ||||
9.Lot # 012496-5 | 84.5 | 2.5 | 3.0 | 10.0 |
10.Lot # 012496-6 | 83.25 | 3.75 | 3.0 | 10.0 |
11.Lot # 012496-7 | 82.0 | 5.0 | 3.0 | 10.0 |
12.Lot # 012496-9 | 81.5 | 2.5 | 6.0 | 10.0 |
13.Lot # 012496-10 | 80.25 | 3.75 | 6.0 | 10.0 |
14.Lot # 012496-11 | 79.0 | 5.0 | 6.0 | 10.0 |
15.Lot # 012496-13 | 77.0 | 2.5 | 10.5 | 10.0 |
16.Lot # 012496-14 | 75.75 | 3.75 | 10.5 | 10.0 |
17.Lot # 012496-15 | 74.5 | 5.0 | 10.5 | 10.0 |
参比制剂 | ||||
4.参比 # 95Z082TE参比制剂 | 75.75 | 3.75 | 10.5 | 10.0 |
8.参比 # 95Z135E2参比制剂 | 93.5* | 0.0 | 1.5 | 5.0 |
制剂ID | 皮肤/扩散池的# | TS数据 | E2数据 | ||||
Q24* | Q24(参比)X | 比例 | Q24* | Q24(参比)X | 比例 | ||
待测制剂 | |||||||
9.Lot#012496-5 | 3/12 | 14.2±6.1 | 23.0±0.3 | 0.60±0.1 | 1.4±0.5 | 5.2±1.8 | 0.27±0.04 |
10.Lot#012496-6 | 3/12 | 24.2±9.0 | 23.0±0.3 | 1.06±0.2 | 1.5±0.5 | 5.2±1.8 | 0.29±0.06 |
11.Lot#012496-7 | 3/12 | 28.1±9.5 | 23.0±9.3 | 1.24±0.2 | 1.4±0.4 | 5.2±1.8 | 0.26±0.04 |
12.Lot#012496-9 | 3/10 | 13.2±2.9 | 23.2±8.4 | 0.58±0.2 | 2.6±0.5 | 4.7±1.6 | 0.57±0.14 |
13.Lot#012496-10 | 3/10 | 18.2±4.5 | 23.2±8.4 | 0.81±0.3 | 2.4±0.6 | 4.7±1.6 | 0.54±0.20 |
14.Lot#012496-11 | 3/11 | 26.3±7.9 | 23.2±8.4 | 1.13±0.2 | 2.7±0.7 | 4.7±1.6 | 0.58±0.12 |
15.Lot#012496-13 | 3/12 | 14.4±7.8 | 22.5±10.0 | 0.61±0.1 | 6.2±3.2 | 5.9±2.4 | 0.99±0.19 |
16.Lot#012496-14 | 3/12 | 21.4±10.9 | 22.5±10.0 | 0.93±0.1 | 6.2±3.1 | 5.9±2.4 | 0.99±0.15 |
17.Lot#012496-15 | 3/12 | 26.6±10.6 | 22.5±10.0 | 1.20±0.3 | 6.0±2.2 | 5.9±2.4 | 1.0±0.28 |
Claims (10)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/683,892 | 1996-07-19 | ||
US08/683,892 US5783208A (en) | 1996-07-19 | 1996-07-19 | Transdermal drug delivery matrix for coadministering estradiol and another steroid |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100831783A Division CN100536835C (zh) | 1996-07-19 | 1997-07-02 | 用于雌二醇与另一种类固醇物质共同给药的透皮释药基质 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1225568A true CN1225568A (zh) | 1999-08-11 |
CN1204859C CN1204859C (zh) | 2005-06-08 |
Family
ID=24745888
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100831783A Expired - Fee Related CN100536835C (zh) | 1996-07-19 | 1997-07-02 | 用于雌二醇与另一种类固醇物质共同给药的透皮释药基质 |
CNB971965633A Expired - Fee Related CN1204859C (zh) | 1996-07-19 | 1997-07-02 | 用于雌二醇与另一种类固醇物质共同给药的透皮释药基质 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100831783A Expired - Fee Related CN100536835C (zh) | 1996-07-19 | 1997-07-02 | 用于雌二醇与另一种类固醇物质共同给药的透皮释药基质 |
Country Status (21)
Country | Link |
---|---|
US (1) | US5783208A (zh) |
EP (1) | EP0921774B1 (zh) |
JP (2) | JP4212115B2 (zh) |
KR (1) | KR100628796B1 (zh) |
CN (2) | CN100536835C (zh) |
AT (1) | ATE339172T1 (zh) |
AU (1) | AU714590B2 (zh) |
BR (1) | BR9710738A (zh) |
CA (1) | CA2259532C (zh) |
DE (1) | DE69736671T2 (zh) |
DK (1) | DK0921774T3 (zh) |
ES (1) | ES2271970T3 (zh) |
HK (2) | HK1020864A1 (zh) |
HU (1) | HUP9904369A3 (zh) |
IL (1) | IL127708A (zh) |
NO (1) | NO325232B1 (zh) |
NZ (1) | NZ333558A (zh) |
PL (1) | PL188009B1 (zh) |
PT (1) | PT921774E (zh) |
WO (1) | WO1998003137A1 (zh) |
ZA (1) | ZA976035B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1997375B (zh) * | 2004-04-28 | 2010-09-22 | 亨特-弗莱明有限公司 | 经皮类固醇制剂 |
CN101370453B (zh) * | 2005-12-14 | 2013-12-18 | 努沃研究公司 | 用于皮肤输送药物的组合物和方法 |
Families Citing this family (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5252334A (en) * | 1989-09-08 | 1993-10-12 | Cygnus Therapeutic Systems | Solid matrix system for transdermal drug delivery |
US6407082B1 (en) * | 1996-09-13 | 2002-06-18 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of a vitamin D compound |
US20020048596A1 (en) * | 1994-12-30 | 2002-04-25 | Gregor Cevc | Preparation for the transport of an active substance across barriers |
PL181582B1 (pl) * | 1995-06-07 | 2001-08-31 | Ortho Mcneil Pharm Inc | Plaster na skóre do zapobiegania owulacji u kobiety oraz plaster na skóre do przeprowadzania hormonalnej terapii substytucyjnej PL PL PL PL PL PL PL PL |
US6034074A (en) | 1996-09-13 | 2000-03-07 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of a Vitamin D compound |
US6028064A (en) | 1996-09-13 | 2000-02-22 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of progestin products |
US6511970B1 (en) | 1996-09-13 | 2003-01-28 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium |
US6765002B2 (en) | 2000-03-21 | 2004-07-20 | Gustavo Rodriguez | Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium |
US6248358B1 (en) | 1998-08-25 | 2001-06-19 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets and methods of making and using the same |
US8765177B2 (en) * | 1997-09-12 | 2014-07-01 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
US7153845B2 (en) * | 1998-08-25 | 2006-12-26 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
US6624200B2 (en) | 1998-08-25 | 2003-09-23 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
DE19834007C1 (de) * | 1998-07-29 | 2000-02-24 | Lohmann Therapie Syst Lts | Estradiolhaltiges Pflaster zur transdermalen Applikation von Hormonen und seine Verwendung |
KR100464601B1 (ko) * | 1998-10-23 | 2004-12-31 | 이데아 악티엔게젤샤프트 | 페이로드를 증가시키고, 분리/결합율을 제어하기 위한 거대 분자 결합체 및 복합응집체의 생장, 시험 및 사용방법 |
US6984404B1 (en) | 1998-11-18 | 2006-01-10 | University Of Florida Research Foundation, Inc. | Methods for preparing coated drug particles and pharmaceutical formulations thereof |
US6835866B1 (en) | 1998-12-10 | 2004-12-28 | Board Of Regents, The University Of Texas Systems | Compositions and methods of modulating cholesterol metabolism |
EP1031347B1 (en) | 1999-01-27 | 2002-04-17 | Idea Ag | Transnasal transport/immunisation with highly adaptable carriers |
SI1031346T1 (en) | 1999-01-27 | 2002-08-31 | Idea Ag | Noninvasive vaccination through the skin |
US6297337B1 (en) | 1999-05-19 | 2001-10-02 | Pmd Holdings Corp. | Bioadhesive polymer compositions |
EP1754488A1 (en) | 1999-05-24 | 2007-02-21 | Introgen Therapeutics, Inc. | Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases |
US6406745B1 (en) | 1999-06-07 | 2002-06-18 | Nanosphere, Inc. | Methods for coating particles and particles produced thereby |
WO2001001962A1 (en) * | 1999-07-05 | 2001-01-11 | Idea Ag. | A method for the improvement of transport across adaptable semi-permeable barriers |
US20010044431A1 (en) * | 2000-03-21 | 2001-11-22 | Rodriguez Gustavo C. | Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium |
WO2001080796A1 (en) | 2000-04-26 | 2001-11-01 | Watson Pharmaceuticals, Inc. | Minimizing adverse experience associated with oxybutynin therapy |
US7029694B2 (en) | 2000-04-26 | 2006-04-18 | Watson Laboratories, Inc. | Compositions and methods for transdermal oxybutynin therapy |
US20030124177A1 (en) * | 2000-04-26 | 2003-07-03 | Watson Pharmaceuticals, Inc. | Compositions and methods for transdermal oxybutynin therapy |
US7179483B2 (en) * | 2000-04-26 | 2007-02-20 | Watson Pharmaceuticals, Inc. | Compositions and methods for transdermal oxybutynin therapy |
US10293056B1 (en) | 2000-05-24 | 2019-05-21 | Board Of Regents, The University Of Texas System | Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases |
US20040092494A9 (en) * | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
CN1541112A (zh) * | 2001-08-10 | 2004-10-27 | �ù���ҩ��ʽ���� | 经皮吸收制剂 |
KR20030041596A (ko) * | 2001-11-20 | 2003-05-27 | 삼일페인트공업 주식회사 | 의료용 팻치에 적용되는 아크릴 점착제의 제조방법 |
US7921999B1 (en) | 2001-12-20 | 2011-04-12 | Watson Laboratories, Inc. | Peelable pouch for transdermal patch and method for packaging |
US7473432B2 (en) * | 2002-10-11 | 2009-01-06 | Idea Ag | NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery |
WO2006050926A2 (en) * | 2004-11-12 | 2006-05-18 | Idea Ag | Extended surface aggregates in the treatment of skin conditions |
US7833979B2 (en) * | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
US10137135B2 (en) * | 2005-08-15 | 2018-11-27 | Allergan Sales, Llc | Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith |
SI1937276T1 (sl) | 2005-10-12 | 2013-04-30 | Unimed Pharmaceuticals, Llc C/O Abbott Laboratoires 100 Abbott Park Road | Izboljšani testosteronski gel in postopek uporabe |
JP2009516718A (ja) * | 2005-11-23 | 2009-04-23 | ウニベルジテート チューリッヒ | 経皮アレルゲン投与によるアレルギー治療 |
WO2007092944A2 (en) * | 2006-02-08 | 2007-08-16 | Introgen Therapeutics, Inc. | Compositions and methods involving gene therapy and proteasome modulation |
US9481912B2 (en) | 2006-09-12 | 2016-11-01 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and identifying nucleic acid sequences in biological samples |
US8097419B2 (en) | 2006-09-12 | 2012-01-17 | Longhorn Vaccines & Diagnostics Llc | Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009 |
US9598462B2 (en) | 2012-01-26 | 2017-03-21 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
US8080645B2 (en) | 2007-10-01 | 2011-12-20 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection/transport compositions and methods |
AR063384A1 (es) * | 2006-10-25 | 2009-01-28 | Amgen Inc | Agentes terapeuticos a base de peptidos derivados de toxinas |
WO2008106646A2 (en) * | 2007-03-01 | 2008-09-04 | Introgen Therapeutics, Inc | Methods and formulations for topical gene therapy |
PL2191001T3 (pl) | 2007-04-09 | 2017-01-31 | University Of Florida Research Foundation, Inc. | Kompozycje wektora RAAV mające białka kapsydu zmodyfikowane tyrozyną i sposoby ich zastosowania |
AU2008262490B2 (en) * | 2007-05-22 | 2011-11-17 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
US9683256B2 (en) | 2007-10-01 | 2017-06-20 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system |
US11041215B2 (en) | 2007-08-24 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | PCR ready compositions and methods for detecting and identifying nucleic acid sequences |
WO2009029686A1 (en) | 2007-08-27 | 2009-03-05 | Longhorn Vaccines & Diagnostics Llc | Immunogenic compositions and methods |
US10004799B2 (en) | 2007-08-27 | 2018-06-26 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
CA2861667C (en) | 2007-10-01 | 2017-06-13 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system and methods of use |
US11041216B2 (en) | 2007-10-01 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples |
WO2010135714A2 (en) | 2009-05-22 | 2010-11-25 | The Methodist Hospital Research Institute | Methods for modulating adipocyte expression using microrna compositions |
US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
DK2826860T3 (en) | 2010-04-23 | 2018-12-03 | Univ Massachusetts | CNS targeting AAV vectors and methods for their use |
WO2011133901A2 (en) | 2010-04-23 | 2011-10-27 | University Of Massachusetts | Aav-based treatment of cholesterol-related disorders |
LT2561067T (lt) | 2010-04-23 | 2019-03-12 | University Of Florida Research Foundation, Inc. | Raav-guanilato ciklazės kompozicijos ir būdai, skirti leberio įgimtosios amaurozės-1 (lca1) gydymui |
EP2686340A2 (en) | 2011-03-16 | 2014-01-22 | Amgen Inc. | Potent and selective inhibitors of nav1.3 and nav1.7 |
EP3318635A1 (en) | 2011-04-21 | 2018-05-09 | University of Massachusetts | Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies |
US10149834B2 (en) | 2011-12-01 | 2018-12-11 | Teikoku Seiyaku Co., Ltd. | Ropinirole-containing adhesive patch |
TWI611817B (zh) * | 2011-12-01 | 2018-01-21 | 帝國製藥股份有限公司 | 含有羅匹尼羅(ropinirole)之貼附劑 |
TW201446792A (zh) | 2013-03-12 | 2014-12-16 | Amgen Inc | Nav1.7之強效及選擇性抑制劑 |
EP3750907A3 (en) | 2014-03-18 | 2021-04-28 | University of Massachusetts | Raav-based compositions and methods for treating amyotrophic lateral sclerosis |
US10975391B2 (en) | 2014-04-25 | 2021-04-13 | University Of Massachusetts | Recombinant AAV vectors useful for reducing immunity against transgene products |
JP6842410B2 (ja) | 2014-10-03 | 2021-03-17 | ユニバーシティ オブ マサチューセッツ | 新規の高効率ライブラリーにより同定されるaavベクター |
CN107073051B (zh) | 2014-10-21 | 2021-08-24 | 马萨诸塞大学 | 重组aav变体及其用途 |
EP3233131A1 (en) | 2014-12-16 | 2017-10-25 | Board of Regents of the University of Nebraska | Gene therapy for juvenile batten disease |
US9976136B2 (en) | 2015-05-14 | 2018-05-22 | Longhorn Vaccines And Diagnostics, Llc | Rapid methods for the extraction of nucleic acids from biological samples |
JP2019507582A (ja) | 2015-12-04 | 2019-03-22 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | 免疫療法用のslc45a2ペプチド |
RU2752882C2 (ru) | 2016-03-03 | 2021-08-11 | Юниверсити Оф Массачусетс | Линейная дуплексная днк с закрытым концом для невирусного переноса генов |
JP2019530737A (ja) | 2016-08-23 | 2019-10-24 | アコーオス インコーポレイテッド | ヒト対象において非加齢性聴力障害を治療するための組成物および方法 |
US10457940B2 (en) | 2016-09-22 | 2019-10-29 | University Of Massachusetts | AAV treatment of Huntington's disease |
US11578340B2 (en) | 2016-10-13 | 2023-02-14 | University Of Massachusetts | AAV capsid designs |
US11318190B2 (en) | 2017-05-05 | 2022-05-03 | United States Government As Represented By The Department Of Veterans Affairs | Methods and compositions for treating liver disease |
JP2021519065A (ja) | 2018-03-23 | 2021-08-10 | ユニバーシティ オブ マサチューセッツ | 骨障害を処置するための遺伝子治療法 |
EP3784290A4 (en) | 2018-04-27 | 2022-03-23 | University of Massachusetts | AAV CAPSIDS IDENTIFIED BY SELECTING AN IN VIVO LIBRARY |
WO2020112967A1 (en) | 2018-11-29 | 2020-06-04 | University Of Massachusetts | Modulation of sptlc1 via recombinant adeno-associated vectors |
US20220054655A1 (en) | 2019-02-22 | 2022-02-24 | University Of Massachusetts | Oxr1 gene therapy |
CN114555814A (zh) | 2019-09-13 | 2022-05-27 | 罗特格斯新泽西州立大学 | Aav相容的层粘连蛋白-连接子聚合蛋白 |
AU2021225035A1 (en) | 2020-02-21 | 2022-10-13 | Akouos, Inc. | Compositions and methods for treating non-age-associated hearing impairment in a human subject |
MX2022012279A (es) | 2020-03-31 | 2023-02-23 | Univ Massachusetts | Variantes de capsides de aav y usos de los mismos. |
EP4153301A2 (en) | 2020-05-21 | 2023-03-29 | Board of Regents, The University of Texas System | T cell receptors with vgll1 specificity and uses thereof |
JP2023539574A (ja) | 2020-08-17 | 2023-09-15 | マサチューセッツ インスティテュート オブ テクノロジー | Shank3遺伝子治療アプローチ |
KR20230117177A (ko) | 2020-12-03 | 2023-08-07 | 유니버시티 오브 매사추세츠 | 진행성 골화성 섬유이형성증을 위한 신규 유전자 치료제의개발 |
IL308282A (en) | 2021-05-10 | 2024-01-01 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Pharmaceutical compositions for the treatment of neurological diseases |
WO2023056329A1 (en) | 2021-09-30 | 2023-04-06 | Akouos, Inc. | Compositions and methods for treating kcnq4-associated hearing loss |
WO2023164545A1 (en) | 2022-02-23 | 2023-08-31 | Massachusetts Institute Of Technology | Methods for upregulating shank3 expression |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4954487A (en) * | 1979-01-08 | 1990-09-04 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions |
IL61721A (en) * | 1980-12-16 | 1984-03-30 | Blank Izhak | Nitroglycerin preparations |
US4537776A (en) * | 1983-06-21 | 1985-08-27 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone |
JPS60123417A (ja) * | 1983-12-07 | 1985-07-02 | Nitto Electric Ind Co Ltd | 薬物投与部材 |
JPS6160620A (ja) * | 1984-09-03 | 1986-03-28 | Teijin Ltd | ピログルタミン酸エステル類を含有する医薬品組成物 |
US5296230A (en) * | 1985-02-25 | 1994-03-22 | Rutgers, The State University Of New Jersey | Transdermal fertility control system and process |
US4762851A (en) * | 1985-11-29 | 1988-08-09 | Merck & Co., Inc. | Pyroglutamic acid esters used as dermal penetration enhancers for drugs |
US5023084A (en) * | 1986-12-29 | 1991-06-11 | Rutgers, The State University Of New Jersey | Transdermal estrogen/progestin dosage unit, system and process |
US4994267A (en) * | 1988-03-04 | 1991-02-19 | Noven Pharmaceuticals, Inc. | Transdermal acrylic multipolymer drug delivery system |
GB8811408D0 (en) * | 1988-05-13 | 1988-06-15 | Unilever Plc | Cosmetic composition |
CA2000401C (en) * | 1988-10-11 | 1996-05-28 | Masato Azuma | Percutaneous pharmaceutical preparation |
US5512292A (en) * | 1990-10-29 | 1996-04-30 | Alza Corporation | Transdermal contraceptive formulations methods and devices |
JPH04342532A (ja) * | 1991-05-21 | 1992-11-30 | Sekisui Chem Co Ltd | 経皮吸収貼付剤 |
JP3086288B2 (ja) * | 1991-07-23 | 2000-09-11 | 扶桑薬品工業株式会社 | 経皮吸収製剤 |
JP2948423B2 (ja) * | 1992-08-19 | 1999-09-13 | 富士写真フイルム株式会社 | カリウムイオン分析用イオン選択電極 |
US5460820B1 (en) * | 1993-08-03 | 1999-08-03 | Theratech Inc | Method for providing testosterone and optionally estrogen replacement therapy to women |
WO1995017896A1 (fr) * | 1993-12-27 | 1995-07-06 | Akzo Nobel N.V. | Preparation pour absorption par voie percutanee |
FR2717688B1 (fr) * | 1994-03-28 | 1996-07-05 | Lhd Lab Hygiene Dietetique | Système matriciel transdermique d'administration d'un oestrogène et/ou un progestatif à base d'EVA. |
JPH0827003A (ja) * | 1994-07-22 | 1996-01-30 | Sekisui Chem Co Ltd | 経皮吸収製剤 |
US5780050A (en) * | 1995-07-20 | 1998-07-14 | Theratech, Inc. | Drug delivery compositions for improved stability of steroids |
DE19629468A1 (de) * | 1996-07-11 | 1998-01-15 | Schering Ag | Transdermale therapeutische Systeme |
-
1996
- 1996-07-19 US US08/683,892 patent/US5783208A/en not_active Expired - Lifetime
-
1997
- 1997-07-02 DK DK97933279T patent/DK0921774T3/da active
- 1997-07-02 KR KR1019997000406A patent/KR100628796B1/ko not_active IP Right Cessation
- 1997-07-02 WO PCT/US1997/011673 patent/WO1998003137A1/en active IP Right Grant
- 1997-07-02 BR BR9710738A patent/BR9710738A/pt not_active Application Discontinuation
- 1997-07-02 AT AT97933279T patent/ATE339172T1/de not_active IP Right Cessation
- 1997-07-02 ES ES97933279T patent/ES2271970T3/es not_active Expired - Lifetime
- 1997-07-02 AU AU36503/97A patent/AU714590B2/en not_active Ceased
- 1997-07-02 HU HU9904369A patent/HUP9904369A3/hu unknown
- 1997-07-02 NZ NZ333558A patent/NZ333558A/xx unknown
- 1997-07-02 PL PL33123997A patent/PL188009B1/pl not_active IP Right Cessation
- 1997-07-02 DE DE69736671T patent/DE69736671T2/de not_active Expired - Lifetime
- 1997-07-02 CN CNB2004100831783A patent/CN100536835C/zh not_active Expired - Fee Related
- 1997-07-02 CA CA002259532A patent/CA2259532C/en not_active Expired - Lifetime
- 1997-07-02 JP JP50695598A patent/JP4212115B2/ja not_active Expired - Lifetime
- 1997-07-02 PT PT97933279T patent/PT921774E/pt unknown
- 1997-07-02 EP EP97933279A patent/EP0921774B1/en not_active Expired - Lifetime
- 1997-07-02 IL IL12770897A patent/IL127708A/en not_active IP Right Cessation
- 1997-07-02 CN CNB971965633A patent/CN1204859C/zh not_active Expired - Fee Related
- 1997-07-07 ZA ZA9706035A patent/ZA976035B/xx unknown
-
1999
- 1999-01-15 NO NO19990179A patent/NO325232B1/no not_active IP Right Cessation
-
2000
- 2000-01-03 HK HK00100001A patent/HK1020864A1/xx not_active IP Right Cessation
-
2005
- 2005-11-18 HK HK05110412.4A patent/HK1078470A1/xx not_active IP Right Cessation
-
2006
- 2006-09-26 JP JP2006261578A patent/JP2006342186A/ja not_active Withdrawn
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1997375B (zh) * | 2004-04-28 | 2010-09-22 | 亨特-弗莱明有限公司 | 经皮类固醇制剂 |
CN101370453B (zh) * | 2005-12-14 | 2013-12-18 | 努沃研究公司 | 用于皮肤输送药物的组合物和方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1204859C (zh) | 用于雌二醇与另一种类固醇物质共同给药的透皮释药基质 | |
US4883669A (en) | Transdermal absorption dosage unit for estradiol and other estrogenic steroids and process for administration | |
KR100373451B1 (ko) | 에스트라디올함유패치 | |
CN1129426C (zh) | 经皮吸收类制剂 | |
AU2002365624B2 (en) | Transdermal therapeutic systems containing steroid hormones and propylene glycol monocaprylate | |
HU222499B1 (hu) | Ösztradiol-penetrációfokozó szert tartalmazó szabályozott hatóanyag-leadású tapasz és eljárás előállítására | |
CA2338859C (en) | Estradiol-containing patch for transdermal administration of hormones | |
US20050058695A1 (en) | Norethindrone sustained release formulations and methods associated therewith | |
KR20090101579A (ko) | 펜타닐을 함유한 경피 흡수제 | |
JP2003063955A (ja) | 経皮吸収型貼付剤 | |
US20040037873A1 (en) | Norethindrone sustained release formulations and methods associated therewith | |
AU762589B2 (en) | Estradiol-containing patch for transdermal administration of hormones | |
CN1674914A (zh) | 含有雌性激素的贴剂 | |
JPS6259224A (ja) | 医薬製剤 | |
MXPA99000683A (en) | Matrix for the transdermal release of a pharmacy, to coordinate estradiol and another estero | |
NO880356L (no) | Doseringsenhet for absorpsjon av oestradiol og andre oestrogene stereoider gjennom huden, samt fremgangsmaate til administrering av stereoidene. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: WATSON DRUG COMPANY Free format text: FORMER OWNER: WATTERSON LABORATORY CO.,LTD. Effective date: 20030814 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20030814 Address after: American California Applicant after: Watson Laboratories Inc. Address before: American Utah Applicant before: Waterson Lab., Inc. |
|
ASS | Succession or assignment of patent right |
Owner name: WATSON DRUG COMPANY Free format text: FORMER OWNER: WATTERSON LABORATORY CO.,LTD. Effective date: 20031119 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20031119 Address after: American California Applicant after: Watson Laboratories Inc. Address before: American Utah Applicant before: Waterson Lab., Inc. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050608 Termination date: 20130702 |